The development and in vivo evaluation of a colon drug delivery system using human volunteers

Drug Delivery

Volumn 19, Issue 2, 2012, Pages 81-89

  Zimov, Lucie ^a   Vetch, David ^b   Muselk, Jan ^b   Tembrek, Jan ^c,d  

^a Oncomed Manufacturing As   (Czech Republic)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^d INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

Author keywords

Caffeine; Chitosan; Colonic drug delivery; Eudragit FS 30 D; in vivo evaluation

Indexed keywords

CAFFEINE; CHITOSAN; EUDRAGIT; EXCIPIENT; MICROCRYSTALLINE CELLULOSE;

ADULT; ARTICLE; BIODEGRADABILITY; COLON DRUG DELIVERY SYSTEM; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SALIVA LEVEL; DRUG TARGETING; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PELLET EXTRUSION; PH; PRIORITY JOURNAL; SPHERONIZATION; STOMACH EMPTYING;

ADMINISTRATION, ORAL; ADULT; CAFFEINE; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; COLON; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EXCIPIENTS; GASTRIC EMPTYING; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; REPRODUCIBILITY OF RESULTS; SALIVA; SOLUBILITY;

EID: 84856380090     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.644350     Document Type: Article

References (53)

1. Ahmed IA, Ayres JW. (2011). Comparison of in vitro and in vivo performance of a colonic delivery system. Int J Pharm, 409, 169-177.
2. Akinyinka OO, Sowunmi A, Honeywell R Renwick AG. (2000). The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor Eur J Clin Pharmacol, 56 (2), 153-158. (Pubitemid 30341390)
3. Alkaysi HN, Salem MS, El-Sayed YM. (1988). High performance liquid chromatographic analysis of caffeine concentration in plasma and saliva. J Clin Pharm Ther, 13, 109-115.
4. Baert L, Fanara D, Remon JP, Massart D. (1992). Correlation of extrusion forces, raw materials and sphere characteristics. J Pharm Pharmacol, 44, 676-678.
5. Basit AW. (2005). Advances in Colonic Drug Delivery. Drugs, 65 (14), 1991-2007. (Pubitemid 41324059)
6. Berlin CM, Denson HM, Daniel CH, Ward RM. (1984). Deposition of Dietary Caffeine in Milk, Saliva, and Plasma of Lactating woman. Pediatrics, 73 (1), 59-63. (Pubitemid 14221948)
7. Burg AW. (1975). The effects of caffeine on the human system. Tea Coffee Trade J, 147, 40.
8. Chourasia MK, Jain SK. (2003). Pharmaceutical aaproaches to colon targeted drug delivery systems. J Pharm Pharm Sci, 6, 33-66. (Pubitemid 37207241)
9. Chourasia MK, Jain SK. (2004). Polysaccharides for colon targeted drug delivery. Drug deliv, 11, 129-148. (Pubitemid 38437082)
10. Cole EW, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, Beckert T, Cadé D. (2002). Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm, 231, 83-95. (Pubitemid 33086822)
11. Davis SS, Hardy JG, Fara JW. (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut, 27, 886-892. (Pubitemid 16044258)
12. Dvor̂áĉková K, Rabiŝková M, Gajdziok J, Vetchý D, Muselík J, Bernatoniene, J, Bajerová M, Rottnerová P. (2010). Coated capsules for drug targeting to proximal and distal part of human intestine. Acta Poloniae Pharmaceutica, 67 (2), 191-199.
13. Dvor̂áĉková K, Rabiŝková M, Bajerová M, Muselík J, Gajdziok J. (2011). Coated hard capsules as the pH-dependent drug transport systems to ileo-colonic compartment. Drug Dev Ind Pharm, 37 (10), 1131-1140.
14. Evans DF, Pye G, Bramley R., Clark AG, Dyson TJ, Hardcastle JD. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 29 (8), 1035-1041.
15. Follonier N, Doelker E. (1992). Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms, S.T.P. Pharma sciences, 2 (2), 141-158.
16. Goskonda SR, Upadrashta SM. (1993). Avicel RC-591/Chitosan Beads by Extrusion-Spheronization Technology, Drug Dev Ind Pharm, 19 (8), 915-927. (Pubitemid 23111981)
17. Gupta VK, Beckert TE, Price JC. (2001). A novel pH and time-based multi-unit potential colonic drug delivery system. I. Development. Int J Pharm, 213, 83-91. (Pubitemid 32119464)
18. Häring A, Vetchý D, Janovská L, Krejĉová K, Rabiŝková M. (2008). Differences in Characteristics of Pellets Prepared by Different Pelletization Methods. Drug Dev Ind Pharm, 34, 289-296. (Pubitemid 351431195)
19. Haeckel R. (1990). Relationship between Intraindividual Variation of the Saliva/Plasma-and of the Arteriovenous Concentration Ratio as Demonstrated by the Administration of Caffeine. J Clin Chem Clin Biochem, 28, 279-284. (Pubitemid 20183128)
20. Hejazi R, Amiji M. (2003). Chitosan-based gastrointestinal delivery systems. J Control Release, 89, 161-165.
21. Hellén L, Yliruusi J, Merkku P, Kristoffersson E. (1993). Process variables of instant granulator and spheroniser: I. Physical properties of granules, extrudate and pellets, Int J Pharm, 96, 197-204. (Pubitemid 23233286)
22. Hildebrandt R, Gundert-Remy U, Weber E. (1983). Transfer of caffeine to breastmilk. Br J Clin Pharmacol, 15, 612.
23. ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology, Q2(R1), Current Step 4 version, 2005. Available at: http://www.iC.H.org/products/ guidelines/quality/quality-single/article/ validation-ofanalytical-procedures-text-and-methodology.html. Accessed on 29 June 2011.
24. Ibekwe VC, Fadda MF, Parsons GE, Basit AW. (2006). A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int J Pharm, 308, 52-60. (Pubitemid 43097235)
25. Illum L. (1998). Chitosan and Its Use as a Pharmaceutical Excipient. Pharm Res, 15 (9), 1326-1331. (Pubitemid 28427917)
26. Iruín A, Fernández-Arévalo M, Álvarez- Fuéntes J. (2005). Elaboration and "In Vitro" Characterization of 5-ASA Beads. Drug Dev Ind Pharm, 31, 231-239. (Pubitemid 40315718)
27. Jose S, Prema MT, Chacko AJ, Cinu Thomas S, Souto EB. (2011). Colon specific chitosan microspheres for chronotherapy of chronic stable angina. Colloid Surface B, 83, 277-283.
28. Khan MS, Sridhar BK, Srinatha A. (2010). Development and Evaluation of ph-Dependent Micro Beads for Colon Targeting. Indian J Pharm Sci, 72 (1), 18-23.
29. Kleinebudde P. (1994). Shrinking and swelling properties of pellets containing microcrystalline cellulose and low substituted hydroxypropylcellulose. I.: Shrinking properties. Int J Pharm, 109, 209-219. (Pubitemid 24240116)
30. Koysooko R, Ellis EF, Levy G. (1974). Relationship between theophylline concentration in plasma and saliva in man. Clin Pharmac Ther, 15, 454-460.
31. Lee TC, Charles BG, Steer PA, Flenady VJ. (1996). Saliva as a Valid Alternative to Serum in Monitoring Intravenous Caffeine Treatment for Apnea of Prematurity. Ther Drug Monit, 18, 288-293. (Pubitemid 26163280)
32. Li X, Xia W. (2011). Effect of concentration, degree of deacetylation and molecular weight on emulsifying properties of chitosan. Int J Biol Macromol, 48, 768-772.
33. Mehta KA, Kislalioglu MS, Phuapradit W, Malick AW and Shah NH. (2000). Effect of formulation and process variables on porosity parameters and release rates from a multi unit erosion matrix of a poorly soluble drug. J Control Release, 63 (1-2), 201-211. (Pubitemid 30046955)
34. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, Yoshikawa Y, Takada K. (1998). Evaluation of intestinal pressurecontrolled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release, 52, 119-129. (Pubitemid 28123179)
35. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. (1981). Plasma and Salivary Pharmacokinetics of Caffeine in Man. Eur J Clin Pharmacol, 21, 45-52. (Pubitemid 12237829)
36. Parsons WD, Neis AH. (1978). Effect of smoking on caffeine clearance. Clin Pharmacol Ther, 24 (1), 40-45. (Pubitemid 8407209)
37. Patel MM, Amin AF. (2011). Design and Optimization of Colon-Targeted System of Theophylline for Chronotherapy of Nocturnal Asthma, J Pharm Sci, 100 (5), 1760-1772.
38. Pillay V, Fassihi R. (1999). In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. I. Comparison of pH-responsive drug release and associated kinetics. J Control Release, 59, 229-242. (Pubitemid 29199928)
39. Pinto JF. (2010). Site-specific drug delivery systems within the gastrointestinal tract: From the mouth to the colon. Int J Pharm, 395, 44-52.
40. Podczeck F, Rahman SR, Newton JM. (1999). Evaluation of standardised procedure to assess the shape of pellets using image analysis. Int J Pharm, 192, 123-138. (Pubitemid 29531547)
41. Raghavan CV, Muthulingam C, Jenita JAJL, Ravi TK. (2002). An in Vitro and in Vivo Investigation into the Suitability of Bacterially Trigerred Delivery System for Colon Targeting. Chem Pharm Bull, 50 (7), 892-895. (Pubitemid 41694862)
42. Rudolph MA, Klein S, Beckert TE, Petereit H-U, Dressmann JB. (2001). A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm, 51, 183-190. (Pubitemid 32422095)
43. Santos H, Veiga F, Pina M, Podczeck F, Sousa J. (2002). Physical properties of chitosan pellets produced by extrusion-spheronisation: influence of formulation variables. Int J Pharm, 246, 153-169. (Pubitemid 35247988)
44. Sinha VR, Agraval MK, Kumria R. (2005). Influence of formulation and excipient variables on the pellet properties prepared by extrusion spheronization. Curr Drug Del, 2, 1-8. (Pubitemid 40590916)
45. Sinha VR, Kumria R. (2001). Polysaccharides in colon-specific drug delivery. Int J Pharm, 224, 19-38. (Pubitemid 32706482)
46. Sinha VR, Kumria R. (2002). Binders for colon specific drug delivery: an vitro evaluation. Int J Pharm, 249, 23-31. (Pubitemid 35333429)
47. Sousa JJ, Sousa A, Podczeck F, Newton JM. (2002). Factors influencing the physical characteristics of pellets obtained by extrusionspheronization. Int J Pharm, 232, 91-106. (Pubitemid 34076756)
48. Steckel H, Mindermann-Nogly F. (2004). Production of chitosan pellets by extrusion/spheronization. Eur J Pharm Biopharm, 57(1) 107-14. (Pubitemid 38058809)
49. Toong, C.L., Bruce G. Ch, Steer P.A. (1996). Saliva as a Valid Alternative to Serum in Monitoring Intravenous Caffeine Treatment for Apnea of Prematurity. Ther Drug Monit, 18, 288-293. (Pubitemid 26163280)
50. Vertommen J, Rombaut P, Kinget R. (1998). Internal and external structure of pellets made in a rotary processor. Int J Pharm, 161, 225-236. (Pubitemid 28095706)
51. Vervaet C, Remon JP. (1996). Influence of impeller design, method of screen performation and perforation geometry on the quality of pellets made by extrusion-spheronisation. Int J Pharm, 133, 29-37. (Pubitemid 26163329)
52. Wilding IR, Hardy JG, Sparow RA, Davis SS, Daly PB, English JR (1992). In vivo evaluation of enteric coated naproxen tablets using gamma scintigraphy. Pharm Res, 9, 1436-1441.
53. Zylber-Katz E, Granit L, Levy M. (1984). Relationship between caffeine concentrations in plasma and saliva. Clin Pharmacol Ther, 36(1), 133-137. (Pubitemid 14091703)